Microgliosis is prominent in Rasmussen's encephalitis (RE), a disease with severe seizure activity. However, it is unclear if microglial activation is similar with different histopathologic substrates. Iba1-immunolabelled microglial activation was assessed in neocortex from pediatric epilepsy surgery patients with RE (n = 8), cortical dysplasia (CD; n = 6) and tuberous sclerosis complex (TSC; n = 6). Microglial reactivity was increased, in severely affected RE areas (29% labeling) compared with minimally affected areas of RE cases (15%) and cases of TSC (14%) and CD (12%). There was no qualitative association of Iba1 immunolabelling with the presence of CD8 + cytotoxic T-cells and no statistical association with clinical epilepsy variables, such as seizure duration or frequency. Iba1 appears to be an excellent marker for detecting extensive microglial activation in patients with RE. In addition, this study supports the notion that Iba1-labeled microglial activation is increased in patients with active RE, compared with cases of CD and TSC.
Introduction
A syndrome of severe epilepsy and progressive hemispheric dysfunction, usually occurring in children, is named Rasmussen's encephalitis (RE), after Theodore Rasmussen (Rasmussen et al., 1958) . The origin of the disease is unknown. Suggestions have been made implicating a viral infection of the brain or an autoimmune process as the cause, but no apparent consensus as to etiology has been reached (Rasmussen, 1978; Bien et al., 2005; Power et al., 1990; Rogers et al., 1994; Vinters et al., 1993; Farrell et al., 1995) . T-cells dominate the inflammatory response, and lately cytotoxic T-cell attack on neurons and astrocytes has been proposed as being a key pathogenetic mechanism (Bien et al., 2002; Bauer et al., 2007) . Interestingly Pardo et al. (2004) described a "significant heterogeneity in the stages of cortical pathology and the multifocal nature of the disease", demonstrating various stages of inflammation present in the brain of patients with RE (Pardo et al., 2004) . The pathologic change in RE is almost exclusively confined to one cerebral hemisphere, though given that the "unaffected" cerebral hemisphere is only rarely biopsied, the degree of its involvement may be underestimated (Larner and Anderson, 1995; Hart et al., 1998) . Signs of bilateral inflammatory changes in both cerebral hemispheres have been described in a few patients with RE (Robitaille, 1991; Chinchilla et al., 1994) . Pathologic findings can range from an active disease stage with inflammation and the presence of microglial nodules, lymphocytic perivascular cuffing, neuronophagia, astrocytic activation, and glial scarring, to more subtle changes with various levels of neuronal loss and some gliosis, and moderate perivascular inflammation with or without microglial nodules. Whether the inflammatory changes observed in the brain in RE are primary or a secondary reactive response to chronic seizures is still not clarified (Antel and Rasmussen, 1996) .
Extensive microglial activation is a well described phenomenon in RE and a hallmark of this disease (Banati et al., 1999) . Reactive microglia display multiple changes as a consequence of their activation, including altered morphology, cellular proliferation, change in antigen expression and synthesis of a variety of active molecules (Streit et al., 1999) . To study microglial activation in RE, antibodies against ionized calcium binding adaptor molecule 1 (Iba1), an EF hand calcium binding molecule, were applied as an immunohistochemical marker. The general function of the Iba1 molecule is not well described, although it appears to be involved in membrane ruffling believed to be related to cell motility and phagocytosis by microglia/macrophages and activation of microglia (Imai and Kohsaka, 2002; Ohsawa et al., 2000) . In the brain, Iba1 is considered a 
